Cellino Biotech developing tech to help scale stem cell therapies
Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for patients.
Stem cell tourism goes domestic
The U.S. has 351 stem cell clinics making an awful lot of businesses making marketing claims about stem cell interventions,” said Leigh Turner, coauthor of the study and a bioethicist at University of Minnesota.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CardioCell developing stem cell therapy for chronic heart failure
CardioCell's in Phase 2a trials with its stem cell therapy for chronic heart failure. Its approach is to infuse stem cells into a patient's system taht stimulate the heart cells into to working again.
First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now?
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But the company isn’t too worried about what that might mean just yet. Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 […]